The startup develops stem cell therapies derived from human cord blood to treat brain injuries in newborns. Their products target conditions such as oxygen deprivation, inflammation, and hemorrhage, providing timely interventions for infants affected by traumatic brain injuries and related disorders.
Funding
Funding not disclosed
Founders
Product
Problem
Brain injuries in newborns, resulting from conditions like oxygen deprivation, inflammation, and hemorrhage, can lead to cerebral palsy, the most frequent disability in childhood. Current treatments offer only symptomatic and supportive care, leaving a significant unmet need for causative therapies.
Solution
BrainRepair UG develops stem cell therapies derived from human cord blood to address brain injuries in newborns and infants. Their investigational products aim to provide early intervention for conditions such as cerebral palsy. The company's stem cell treatments have received Orphan Medicinal Product Designations from the European Commission and the European Medicines Agency for the treatment of brain injury in newborn infants. BrainRepair UG focuses on developing causative cell treatments to improve the lives of children and teenagers affected by brain injuries.
Target Audience
The primary target audience includes newborn infants and children suffering from brain injuries, as well as their families and healthcare providers.
Features
- Stem cell therapies derived from human cord blood
- Investigational treatments targeting brain injury in newborns and infants
- Focus on causative treatments for cerebral palsy
- Orphan Medicinal Product Designations from the European Commission and the European Medicines Agency